Challenging Times For Definitive Healthcare: Analysts Highlight Sluggish Growth And Recovery Efforts In Q4 Analysis
Challenging Times For Definitive Healthcare: Analysts Highlight Sluggish Growth And Recovery Efforts In Q4 Analysis
Wednesday, Definitive Healthcare Corp (NASDAQ:DH) reported fourth-quarter 2023 adjusted EPS of $0.07, missing the consensus of $0.08.
週三，Definitive Healthcare Corp（納斯達克股票代碼：DH）公佈的2023年第四季度調整後每股收益爲0.07美元，未達到0.08美元的共識。
The healthcare commercial intelligence company reported sales of $65.93 million, up 9% Y/Y, missing the consensus of $66.02 million.
這家醫療商業情報公司報告銷售額爲6,593萬美元，同比增長9％，未達到預期的6602萬美元。
In the fourth quarter, Definitive Healthcare grew its enterprise client base by 28, or 5% Y/Y, ending the quarter with 565 enterprise customers, defined as those customers with more than $100,000 in annual recurring revenue.
在第四季度，Definitive Healthcare的企業客戶群增長了28個，同比增長了5％，在本季度末有565個企業客戶，定義爲年經常性收入超過10萬美元的客戶。
Guidance: Definitive Health expects first quarter fiscal year 2024 revenue of $63 million-$65 million compared to the consensus of $65.70 million.
指導方針：Definitive Health預計2024財年第一季度收入爲6,300萬至6,500萬美元，而市場普遍預期爲6,570萬美元。
The company sees adjusted EPS of $0.07-$0.08 compared to consensus of $0.07, with adjusted operating income of $18.0 million-$19.0 million and adjusted EBITDA of $19.5 million-$20.5 million.
該公司預計調整後的每股收益爲0.07美元至0.08美元，而市場預期爲0.07美元，調整後的營業收入爲1,800萬至1,900萬美元，調整後的息稅折舊攤銷前利潤爲1,950萬至2,050萬美元。
Definitive Healthcare sees fiscal year 2024 revenue of $263 million-$269 million versus the consensus of $269.63 million, with adjusted EPS of $0.37-$0.40 versus the consensus of $0.32
Definitive Healthcare預計，2024財年收入爲2.63億美元至2.69億美元，而市場普遍預期爲2.6963億美元，調整後每股收益爲0.37美元至0.40美元，而市場預期爲0.32美元
The company expects 2024 adjusted operating income of $78 million-$82.0 million, with an adjusted EBITDA of $84 million-$88.0 million.
該公司預計，2024年調整後的營業收入爲7,800萬至8,200萬美元，調整後的息稅折舊攤銷前利潤爲8400萬美元至8,800萬美元。
Canaccord Genuity notes that despite a disappointing guidance update, Definitive Healthcare has maintained its resilience, reflecting the inherent profitability in its model and investor confidence in the company's potential to recover and achieve margins comparable to or better than its IPO levels.
Canaccord Genuity指出，儘管最新的指導方針令人失望，但Definitive Healthcare仍保持了其彈性，這反映了其模式固有的盈利能力，也反映了投資者對該公司恢復和實現與首次公開募股水平相當或更好的利潤率的潛力的信心。
The positive aspect is that management is actively taking measures to steer the business back on track. However, the primary concern leading to a HOLD rating is the significant decline in growth, largely influenced by macroeconomic factors, with little improvement anticipated in 2024.
積極的方面是，管理層正在積極採取措施引導業務重回正軌。但是，導致持有評級的主要問題是增長的大幅下降，這主要受宏觀經濟因素的影響，預計2024年幾乎沒有改善。
William Blair writes that despite the persistently challenging macro environment, Definitive faces an extended sales cycle.
威廉·布萊爾寫道，儘管宏觀環境持續充滿挑戰，但Definitive仍面臨着延長的銷售週期。
Nonetheless, management expresses optimism about the value proposition of Definitive's platform, leading to increased demand across all client segments.
儘管如此，管理層對Definitive平台的價值主張表示樂觀，這導致所有客戶群的需求增加。
A notable positive development highlighted is a favorable change in client retention towards the end of the quarter in 2023, continuing into the early months of 2024. The analyst maintains the Outperform rating.
一個值得注意的積極進展是，到2023年本季度末，客戶留存率發生了有利的變化，一直持續到2024年頭幾個月。分析師維持跑贏大盤的評級。
Price Action: DH shares are up 4.8% at $9.65 on the last check Thursday.
價格走勢：在週四的最後一次支票中，DH股價上漲4.8％，至9.65美元。